Results 31 to 40 of about 52,624 (289)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Structured Metadata for Direct Resource Location: A Case Study [PDF]

open access: yes, 2003
This paper proposes that for scientific and technical information resources, a well-structured and high-quality metadata record contains enough information to find that resource on the Internet, and as a consequence, no additional human labour is needed ...
Agrimi, Moira   +5 more
core  

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

open access: yesMolecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath   +13 more
wiley   +1 more source

Performing Art Libraries at Duesseldorf : their role in the field of introducing computer-based information management within the Theatre Museum and the Film Museum [PDF]

open access: yes, 2009
Düsseldorf is the capital of North Rhine-Westphalia, the state with the highest number of inhabitants in Germany. The city has a rich cultural history: The theatre history started in 1485 (the festivities in the context of a princely marriage at ...
Schild, Margret
core  

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Collaborating communities revisited

open access: yesKnjižnica, 2019
Purpose: This article follows up “Collaborating communities: the RDA experience and its implications for common information environments”, published in 2007 in the proceedings of the 11th seminar on Archives, Libraries, Museums held in Poreč, Croatia ...
Gordon Dunsire
doaj   +1 more source

RDA: an innovation in cataloguing [PDF]

open access: yes, 2013
With effect from 31 March 2013, Resource Description and Access (RDA) has become the cataloguing content standard used by the British Library and the Library of Congress.
Hunt, Stuart
core   +2 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy